MNPR Stock — Monopar Therapeutics Inc.: Cash, EV, Pipeline

Share price

$96.47

Market cap

$647.5M

Cash

$105.4M

Enterprise value

$542.1M

Balance sheet

Cash	$105.4M
Debt	$0.0M
Net cash	$105.4M
Enterprise value	$542.1M
Basic shares	6.7M shares
Fully diluted shares	7.4M shares
Fully diluted market cap	$713.0M
Cash per share	$15.73

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MNPR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	MNPR-101-DFO*-89Zr	Phase 1	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—
Feb 12 - Mar 26	MNPR-101-PCTA-177Lu	Phase 1	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ALXN1840

Phase 3 · Active Modality: small molecule

Aliases Tiomolybdate choline

Target copper

Partnerships Alexion Pharmaceuticals, Inc. (AstraZeneca subsidiary): exclusive license agreement (October 23, 2024) granting Monopar rights to ALXN1840; Alexion had previously completed the pivotal Phase 3 and terminated its own ALXN1840 program

Indications

Wilson disease (Phase 3)

Status note Once-daily oral investigational drug for Wilson disease. Alexion completed a pivotal Phase 3 trial, then terminated the program. Monopar licensed the program and initiated a rolling NDA submission on July 22, 2026.

MNPR-101-Zr

Phase 1 · Active Modality: radiopharmaceutical

Target uPAR

Partnerships Excel Diagnostics and Nuclear Oncology Center (EDNOC): collaboration; authorization received June 11, 2025 to conduct imaging studies

Indications

Advanced cancers (diagnostic imaging) (Phase 1)

Status note Humanized monoclonal antibody MNPR-101 conjugated with zirconium for PET imaging of uPAR-expressing tumors.

MNPR-101-Lu

Phase 1 · Active Modality: radiopharmaceutical

Target uPAR

Partnerships NorthStar: long-term non-exclusive master supply agreement (June 2024) for therapeutic radioisotope actinium-225; XOMA (US) LLC: non-exclusive license to humanization technology for MNPR-101

Indications

Advanced cancers (therapeutic) (Phase 1)

Status note Lutetium-labeled MNPR-101 radiopharmaceutical therapeutic targeting uPAR. FDA cleared the IND application on September 26, 2025 for a Phase 1 open-label, multicenter dosimetry and dose-escalation trial.

Per-asset detail extracted from the 10-Q filed 2026-07-31. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	MNPR-101-DFO*-89Zr
Lead indication	Solid Tumor, Adult
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06337084	Phase 1	Active, not recruiting	Sponsor	Monopar Therapeutics	—	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—
NCT06617169	Phase 1	Active, not recruiting	Sponsor	Monopar Therapeutics	—	Solid Tumor, Adult; Bladder Cancer; Urothelial Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Monopar Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	217,595	-46,683	0.95%	2026-08-14
OrbiMed Advisors	157,423	+157,423	0.28%	2026-08-14
Ikarian Capital	47,861	+47,861	0.73%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MNPR — Monopar Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders